A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-07-25
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-26 (study day 22); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 30); relationship: N
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-07-04 (study day 335); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-02 (study day 364); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-08-11 (study day 373); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-16 (study day 378); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-08-24 (study day 386); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-08-28 (study day 390); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-09-28 (study day 421); relationship: not assessed
Data queries
No data queries.